Supernus Pharmaceuticals Inc
$ 55.75
-1.01%
26 Feb - close price
- Market Cap 3,229,352,000 USD
- Current Price $ 55.75
- High / Low $ 56.38 / 54.05
- Stock P/E N/A
- Book Value 18.38
- EPS -0.36
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.02 %
- 52 Week High 59.68
- 52 Week Low 29.16
About
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$63.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-04 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-28 |
| Reported EPS | -0.8 | 0.4 | 0.4363 | 0.5483 | 0.69 | 0.36 | 0.26 | 0.89 | 0.24 | -0.02 | 0.29 | 0.43 |
| Estimated EPS | 0.14 | 0.48 | 0.38 | 0.52 | 0.44 | 0.31 | 0.38 | 0.55 | 0.08 | -0.23 | 0.17 | 0.68 |
| Surprise | -0.94 | -0.08 | 0.0563 | 0.0283 | 0.25 | 0.05 | -0.12 | 0.34 | 0.16 | 0.21 | 0.12 | -0.25 |
| Surprise Percentage | -671.4286% | -16.6667% | 14.8158% | 5.4423% | 56.8182% | 16.129% | -31.5789% | 61.8182% | 200% | 91.3043% | 70.5882% | -36.7647% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SUPN
2026-02-26 02:53:29
Supernus Pharmaceuticals (SUPN) reported a return to a quarterly EPS loss in Q4 2025, with a US$0.07 loss per share despite increased revenue of US$211.6 million. The company's full-year trailing net income swung from a US$73.9 million profit in Q4 2024 to a US$38.6 million loss in Q4 2025, raising concerns about profitability, rising costs, and reliance on a few key products. Analysts project future revenue growth but anticipate shrinking margins and require a significant shift from the current loss trend for the stock to meet its forecast valuation targets.
2026-02-24 21:53:23
Supernus Pharmaceuticals reported a net loss of $4.1 million for the fourth quarter, or $0.07 per share, with adjusted earnings of $0.92 per share and $211.6 million in revenue. For the full fiscal year, the company posted a loss of $38.6 million on revenue of $719 million. Supernus projects its revenue for the upcoming year to be between $840 million and $870 million.
2026-02-24 21:53:23
Supernus Pharmaceuticals increased executive base salaries, granted 2025 bonuses, and expanded performance-based equity awards on February 18, 2026. These changes, effective January 1, 2026, aim to align management's compensation with shareholder interests and company performance. While 2026 bonus targets remained flat, the focus shifted to enhancing long-term incentive opportunities.
2026-02-24 20:53:22
Supernus Pharmaceuticals, Inc. announced record total revenues of $211.6 million for Q4 2025 and $719.0 million for the full year 2025, marking increases of 21% and 9% respectively, driven by strong growth in its four key products, Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The company has resumed new patient initiation for ONAPGO and provided a full-year 2026 guidance forecasting total revenues between $840 million and $870 million. These results reflect significant progress in strategic objectives, including the acquisition of Sage Therapeutics, Inc. and the launch of ONAPGO.
2026-02-24 16:21:00
Supernus Pharmaceuticals (NASDAQ: SUPN) reported strong Q4 CY2025 revenues of $211.6 million, exceeding analyst expectations by 8.4% with a 21.5% year-on-year increase. Despite a GAAP loss of $0.07 per share, which was better than anticipated, the company's full-year revenue guidance fell slightly short of estimates. The robust performance was attributed to growth products, the acquisition of Sage Therapeutics, Inc., and the launch of ONAPGO for Parkinson's disease.
2026-02-24 16:17:00
Supernus Pharmaceuticals, Inc. (SUPN) announced its Q4 revenue reached $211.6 million, surpassing the FactSet estimate of $195.2 million. The company, focused on central nervous system (CNS) diseases, provided earnings guidance for the full year 2026. This report highlights Supernus's financial performance and continued development of treatments for various neurological conditions.
